echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Digestive System Information > Gastroenterology: Prognosis study in patients with inflammatory bowel disease associated with primary sclerosis bileitis.

    Gastroenterology: Prognosis study in patients with inflammatory bowel disease associated with primary sclerosis bileitis.

    • Last Update: 2020-10-27
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    Researchers recently looked at the risk of primary sclerotic bileitis (PSC) in patients with inflammatory bowel disease (IBD).
    between April 2006 and April 2016, researchers followed IBD patients to collect PSC(PSC-IBD) data, which, as of April 2019, covered hospital visits, imaging and endoscopic assessments, surgery, cancer and death.
    the main purpose of this study was to quantify the risk of developing PSC in all IBD subtype patients and to assess its impact on liver and bile disease, IBD-related outcomes and all-cause mortality based on sex, race and age.
    10 years, researchers have collected information on 284,560 IBD patients nationwide, 2,588 of which have PSC.
    total of 31,587 colonectomies, 5608 colorectal cancer (CRC) removals, 6608 gallbladder excisions and 41,055 patient deaths were performed.
    IBD patients developed PSC associated with an increased risk of death and CRC (risk ratio of 3.20 and 2.43, respectively), and the middle age of CRC diagnosis in IBD-PSC patients was lower (59 years vs 69 years).
    compared to patients with pure IBD, if diagnosed with PSC-IBD under 40 years of age, the above-mentioned PSC-IBD patients had a four-fold increased risk of CRC, and PSC-IBD also increased bile tube cancer (HR: 28.46), risk of hepatocellular carcinoma (HR:21.00), pancreatic cancer (HR:5.26) and gallbladder cancer (HR:9.19).
    patients who were examined for PSC-IBD had a lower risk of death associated with liver and pancreatic bile tube cancer (HR, 0.43) than those who did not receive an imaging test.
    the largest difference in mortality between the PSC-IBD group and the IBD group alone were among patients under 40 years of age (risk ratio >7), while those over 60 years of age had a smaller difference (risk ratio of 1.5).
    in PSC-IBD patients, the researchers observed 173 first liver transplants.
    of patients under the age of 40 diagnosed with PSC, liver transplantation and PSC-related events accounted for about 75 per cent of clinical events, compared with 31 per cent over the age of 60.
    increased risk of transplantation or PSC-related death in African and Caribbean populations (HR:2.05) compared to white populations, while the risk of transplantation or death was lower in female patients (HR:0.74).
    study found an increased risk of colon cancer, liver and pancreatic bile tube cancer and death in patients with inflammatory bowel disease associated with primary sclerotic bileitis.
    poor prognosm for people aged 40 and under, men and people of African-Caribbean descent.
    .
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.